Establishment and Validation of CyberKnife Irradiation in a Syngeneic Glioblastoma Mouse Model.
CyberKnife
GL261
glioblastoma
mouse
radiobiology
small animal radiation
stereotactic radiosurgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Jul 2021
08 Jul 2021
Historique:
received:
14
05
2021
revised:
01
07
2021
accepted:
05
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
CyberKnife stereotactic radiosurgery (CK-SRS) precisely delivers radiation to intracranial tumors. However, the underlying radiobiological mechanisms at high single doses are not yet fully understood. Here, we established and evaluated the early radiobiological effects of CK-SRS treatment at a single dose of 20 Gy after 15 days of tumor growth in a syngeneic glioblastoma-mouse model. Exact positioning was ensured using a custom-made, non-invasive, and trackable frame. One superimposed target volume for the CK-SRS planning was created from the fused tumor volumes obtained from MRIs prior to irradiation. Dose calculation and delivery were planned using a single-reference CT scan. Six days after irradiation, tumor volumes were measured using MRI scans, and radiobiological effects were assessed using immunofluorescence staining. We found that CK-SRS treatment reduced tumor volume by approximately 75%, impaired cell proliferation, diminished tumor vasculature, and increased immune response. The accuracy of the delivered dose was demonstrated by staining of DNA double-strand breaks in accordance with the planned dose distribution. Overall, we confirmed that our proposed setup enables the precise irradiation of intracranial tumors in mice using only one reference CT and superimposed MRI volumes. Thus, our proposed mouse model for reproducible CK-SRS can be used to investigate radiobiological effects and develop novel therapeutic approaches.
Identifiants
pubmed: 34298631
pii: cancers13143416
doi: 10.3390/cancers13143416
pmc: PMC8303959
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2016 Mar 15;7(11):12318-30
pubmed: 26848525
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):446-53
pubmed: 25104071
Medicines (Basel). 2018 Aug 14;5(3):
pubmed: 30110927
Cancer Sci. 2018 Jul;109(7):2275-2285
pubmed: 29758120
Front Cell Neurosci. 2018 Nov 12;12:414
pubmed: 30483064
Radiat Res. 2012 Mar;177(3):311-27
pubmed: 22229487
Radiat Res. 2011 Oct;176(4):459-73
pubmed: 21787181
Radiother Oncol. 2015 Sep;116(3):467-72
pubmed: 26163089
J Neurooncol. 2007 Nov;85(2):133-48
pubmed: 17874037
J Neurooncol. 2011 Nov;105(2):191-8
pubmed: 21499912
Neurosurgery. 2021 Jan 13;88(2):E205-E215
pubmed: 33289503
Radiat Res. 2011 Jun;175(6):774-83
pubmed: 21449714
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):254-62
pubmed: 24411596
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):860-6
pubmed: 17011458
Radiother Oncol. 1993 Oct;29(1):60-8
pubmed: 8295989
Cancer Res. 2003 Jul 15;63(14):4021-7
pubmed: 12874001
Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):619-26
pubmed: 7558951
Med Phys. 2014 Feb;41(2):021715
pubmed: 24506606
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):220-8
pubmed: 20005455
Acta Neurochir (Wien). 1982;64(1-2):87-102
pubmed: 7124475
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Mol Neurobiol. 2017 Mar;54(2):1022-1032
pubmed: 26797684
Mamm Genome. 2018 Dec;29(11-12):843-865
pubmed: 30178305
Cancers (Basel). 2020 Aug 19;12(9):
pubmed: 32824974
Radiat Res. 2007 Jan;167(1):80-6
pubmed: 17243316
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575
pubmed: 29383033
Radiat Res. 2010 Apr;173(4):486-93
pubmed: 20334521
Exp Neurol. 2004 Aug;188(2):316-30
pubmed: 15246832
Med Phys. 2015 Nov;42(11):6507-13
pubmed: 26520740
Phys Med. 2015 Sep;31(6):634-41
pubmed: 26004351
World Neurosurg. 2018 Aug;116:505-517
pubmed: 30049045
Cancer Res. 2013 Feb 1;73(3):1201-10
pubmed: 23243025
Cancer Res. 2004 Oct 1;64(19):7144-9
pubmed: 15466212
Curr Oncol. 2019 Jun;26(3):e328-e333
pubmed: 31285676
Cell Death Differ. 2000 Aug;7(8):712-20
pubmed: 10918445
Cureus. 2019 Dec 31;11(12):e6527
pubmed: 31911881
Int J Radiat Biol. 2003 May;79(5):359-66
pubmed: 12943244
Biomed Res Int. 2013;2013:658126
pubmed: 24324970
PLoS One. 2014 Apr 02;9(4):e93650
pubmed: 24695541
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):527-33
pubmed: 19735877
Curr Treat Options Oncol. 2020 Apr 30;21(6):45
pubmed: 32350685
J Neuroimmunol. 2011 Mar;232(1-2):75-82
pubmed: 21056915
J Neurosurg. 1996 Jun;84(6):1033-8
pubmed: 8847568
Transl Oncol. 2012 Aug;5(4):230-7
pubmed: 22937174
Neurosurgery. 2007 Jan;60(1):31-44; discussion 44-5
pubmed: 17228251
World Neurosurg. 2019 Nov;131:e96-e107
pubmed: 31306844
Brain Pathol. 2005 Oct;15(4):297-310
pubmed: 16389942
Exp Neurol. 2014 Apr;254:134-44
pubmed: 24491956
PLoS One. 2015 Oct 06;10(10):e0139596
pubmed: 26440791
Cancer Sci. 2006 Jun;97(6):546-53
pubmed: 16734735
Radiat Oncol. 2018 Jun 1;13(1):104
pubmed: 29859114
Leukemia. 2010 Apr;24(4):679-86
pubmed: 20130602
Acta Neuropathol. 2016 Mar;131(3):365-78
pubmed: 26718201
Front Immunol. 2020 Sep 29;11:571951
pubmed: 33117364
Clin Transl Med. 2018 Oct 16;7(1):33
pubmed: 30327965
Radiother Oncol. 1993 Jun;27(3):229-36
pubmed: 7692473
Cancer Radiother. 2011 Jun;15(3):221-9
pubmed: 21514198
Neurosurg Clin N Am. 1992 Jan;3(1):61-77
pubmed: 1633453
Cancer Res. 2001 Dec 15;61(24):8859-65
pubmed: 11751409
Chin Clin Oncol. 2017 Sep;6(Suppl 2):S12
pubmed: 28917250
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723
Glia. 2016 Jul;64(7):1210-26
pubmed: 27143298
Mil Med Res. 2018 Jun 30;5(1):20
pubmed: 29958545
Strahlenther Onkol. 2016 Nov;192(11):806-814
pubmed: 27402389